Preview

Current Pediatrics

Advanced search

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN

Abstract

NPO «Microgen» developed vaccine «PANDEFLU» — influenza inactivated subunit adsorbed monovalent vaccine, strain A/California/7/2009 (H1N1), for specific prophylaxis of pandemic influenza in different age groups of citizens. Reactogenicity, safety and immunogenicity were analyzed in a study of volunteers 18–60 years old. The article presents results of administration of vaccine «PANDEFLU» in children. The study performed in two clinical centers proves good tolerability, reactogenicity, safety and high immunogenicity of this vaccine.
Key words: children, influenza, influenza virus А/H1N1, inactivated influenza vaccine, reactogenicity, safety, immunogenicity.
(Voprosy sovremennoi pediatrii — Current Pediatrics. – 2010;9(4):106-109)

About the Authors

A.N. Mironov
NPO «Microgen», Moscow
Russian Federation



A.A. Romanova
NPO «Microgen», Moscow
Russian Federation


R.Ya. Meshkova
Clinical Hospital № 1, Smolensk
Russian Federation


I.V. Fel’dblyum
Ye.A. Vagner Perm State Medical Academy
Russian Federation



N.V. Kupina
NPO «Microgen», Moscow
Russian Federation


D.S. Bushmenkov
NPO «Microgen», Moscow
Russian Federation


A.A. Tsaan
NPO «Microgen», Moscow
Russian Federation


References

1. Pandemic influenza preparedness and response: a WHO guidance document. URL: http://www.who.int/csr/disease/influenza/PIPGuidance09.pdf

2. Chan M. World now at the start of 2009 influenza pandemic. Statement to the press by WHO Director-General Dr Margaret Chan. WHO. 11 June 2009.

3. Hirschler В., Kelland К., Deighton В. EU Agency recommends first two H1N1 flu vaccines. Reuters Health Information. Доступно на: http://us.mobile.reuters.com/article/healthNews/idUSTRE58O1UB20090925?ca=rdt

4. СНМР variation assessment report: European Medicines Agency. URL:http://Doc.Ref.EMEA/748707/2009. 20 November 2009.

5. Nicoll A., Ammon A., Amato A. et al. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. Public Health. 2010; 124 (1): 14–23.

6. Беляев А.Л., Слепушкин А.Н. Современное состояние проблемы гриппа и острых респираторных заболеваний (ОРЗ). Сборник Материалов VIII съезда Всероссийского общества эпидемиологов, микробиологов и паразитологов. М. 2004; 2: 232.

7. Медуницин Н.В. Вакцинология. М.: Триада–Х. 2010. 512 р.

8. Белоусов Ю.Б. Планирование и проведение клинических исследований лекарственных средств. М. 2000. Р. 261–560.

9. Национальный стандарт Российской Федерации № 232-ст. от 27.09.2005 г. «Надлежащая клиническая практика». М. 2005.

10. Приказ МЗ РФ № 266 от 19.06.2003 г. «Правила клинической практики в Российской Федерации». Российская газета. 2003; 135.

11. Федеральный закон № 122-ФЗ от 22.08.2004 «О лекарственных средствах». Доступно на: http://www.mma.ru/article/id11967.


Review

For citations:


Mironov A., Romanova A., Meshkova R., Fel’dblyum I., Kupina N., Bushmenkov D., Tsaan A. EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN. Current Pediatrics. 2010;9(4):106-109.

Views: 615


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)